Year Founded
2020
Ownership
Private
Employees
~50
Therapeutic Areas
ImmunologyRare DiseasesNeurologyEndocrinology
Stage
Preclinical
Modalities
Non-viral gene therapySmall interfering RNA (siRNA)

Code Biotherapeutics General Information

Developing non-viral gene delivery platform for genetic medicines. Lead programs in DMD and T1D advancing towards IND-enabling studies.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office

Drug Pipeline

No pipeline data available

For full access to Code Biotherapeutics's pipeline data

Book a demo

Key Partnerships

Takeda

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Code Biotherapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Code Biotherapeutics's complete valuation and funding history, request access »

Code Biotherapeutics Investors

Takeda Ventures
Investor Type: Venture Capital
Holding: Minority
Amgen Ventures
Investor Type: Venture Capital
Holding: Minority
UCB Ventures
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »